Successful
use of Ustekinumab in a Patient with #Psoriasis, Psoriatic Arthritis
and Systemic Lupus Erythematosus: A Case report and Review of literature
by Aman Kugasia in BJSTR
Abstract
Studies have demonstrated the role of TH-17 pathway in the
pathogenesis of Systemic Lupus Erythematosus (SLE). Ustekinumab, a
monoclonal antibody, binds and inhibits p40 subunit of IL-12 and 23,
leading to IL-17 blockage, causing inhibition of TH-17 signaling
pathway.
Ustekinumab has rarely been used in the treatment of SLE. Herein, we
discuss a patient with long standing history of Psoriasis and PsoriaticArthritis, which was successfully being managed with anti TNF therapy.
He was later diagnosed to have concomitant SLE. His persistently active
and aggressive psoriatic lesions, arthritis and thrombocytopenia posed
an interesting therapeutic dilemma. Fortunately his psoriatic lesions,
arthritis and thrombocytopenia responded well to ustekinumab.
Methotrexate was added to his regimen after improvement and he remained
in remission on this therapy. Further clinical studies are warranted to
investigate the role of TH-17 blocking agents in SLE.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.